Trial Outcomes & Findings for A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B (NCT NCT03038113)

Last Updated: 2020-12-24

Results Overview

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs of Special Interest were defined as: i.) elevated ALT/AST in combination with elevated bilirubin/clinical jaundice, ii.) suspected transmission of infectious agent by the study drug, iii.) severe injection site reactions, iv.) ALT elevation ≥10x ULN, v.) creatinine elevation ≥1.5x ULN or ≥50% from baseline.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

119 participants

Primary outcome timeframe

Up to day 113

Results posted on

2020-12-24

Participant Flow

Participant milestones

Participant milestones
Measure	Part 1 - RO7062931 0.1 mg/kg Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Overall Study STARTED	8	8	8	8	8	8	12	6	7	6	14	7	4	15
Overall Study COMPLETED	8	8	7	8	8	8	11	6	7	6	14	7	4	14
Overall Study NOT COMPLETED	0	0	1	0	0	0	1	0	0	0	0	0	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1 - RO7062931 0.1 mg/kg Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Overall Study Withdrawal by Subject	0	0	1	0	0	0	0	0	0	0	0	0	0	1
Overall Study Lost to Follow-up	0	0	0	0	0	0	1	0	0	0	0	0	0	0

Baseline Characteristics

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=12 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M n=6 Participants Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M n=7 Participants Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M n=6 Participants Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW n=14 Participants Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W n=7 Participants Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW n=4 Participants Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo n=15 Participants Participants received SC placebo matched to RO7062931 over a 4-week period.	Total n=119 Participants Total of all reporting groups
Age, Continuous	29.8 Years STANDARD_DEVIATION 11.9 • n=5 Participants	29.0 Years STANDARD_DEVIATION 11.4 • n=7 Participants	34.0 Years STANDARD_DEVIATION 11.4 • n=5 Participants	30.4 Years STANDARD_DEVIATION 13.6 • n=4 Participants	24.8 Years STANDARD_DEVIATION 7.9 • n=21 Participants	23.4 Years STANDARD_DEVIATION 3.5 • n=10 Participants	31.6 Years STANDARD_DEVIATION 9.0 • n=115 Participants	42.0 Years STANDARD_DEVIATION 5.3 • n=6 Participants	42.7 Years STANDARD_DEVIATION 11.1 • n=6 Participants	47.8 Years STANDARD_DEVIATION 7.2 • n=64 Participants	46.1 Years STANDARD_DEVIATION 12.1 • n=17 Participants	44.9 Years STANDARD_DEVIATION 8.7 • n=21 Participants	48.5 Years STANDARD_DEVIATION 6.9 • n=22 Participants	44.7 Years STANDARD_DEVIATION 9.0 • n=8 Participants	37.1 Years STANDARD_DEVIATION 12.6 • n=16 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	1 Participants n=6 Participants	2 Participants n=64 Participants	2 Participants n=17 Participants	0 Participants n=21 Participants	1 Participants n=22 Participants	1 Participants n=8 Participants	8 Participants n=16 Participants
Sex: Female, Male Male	8 Participants n=5 Participants	8 Participants n=7 Participants	7 Participants n=5 Participants	8 Participants n=4 Participants	8 Participants n=21 Participants	8 Participants n=10 Participants	12 Participants n=115 Participants	6 Participants n=6 Participants	6 Participants n=6 Participants	4 Participants n=64 Participants	12 Participants n=17 Participants	7 Participants n=21 Participants	3 Participants n=22 Participants	14 Participants n=8 Participants	111 Participants n=16 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	2 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	2 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	5 Participants n=16 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	6 Participants n=5 Participants	8 Participants n=7 Participants	8 Participants n=5 Participants	8 Participants n=4 Participants	8 Participants n=21 Participants	7 Participants n=10 Participants	10 Participants n=115 Participants	6 Participants n=6 Participants	7 Participants n=6 Participants	6 Participants n=64 Participants	14 Participants n=17 Participants	7 Participants n=21 Participants	4 Participants n=22 Participants	15 Participants n=8 Participants	114 Participants n=16 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	0 Participants n=16 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	0 Participants n=16 Participants
Race (NIH/OMB) Asian	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	3 Participants n=21 Participants	4 Participants n=10 Participants	3 Participants n=115 Participants	5 Participants n=6 Participants	6 Participants n=6 Participants	4 Participants n=64 Participants	14 Participants n=17 Participants	6 Participants n=21 Participants	3 Participants n=22 Participants	15 Participants n=8 Participants	68 Participants n=16 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=6 Participants	1 Participants n=6 Participants	1 Participants n=64 Participants	0 Participants n=17 Participants	1 Participants n=21 Participants	1 Participants n=22 Participants	0 Participants n=8 Participants	7 Participants n=16 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	2 Participants n=16 Participants
Race (NIH/OMB) White	4 Participants n=5 Participants	5 Participants n=7 Participants	6 Participants n=5 Participants	5 Participants n=4 Participants	4 Participants n=21 Participants	4 Participants n=10 Participants	9 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	1 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	38 Participants n=16 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	2 Participants n=16 Participants
Race (NIH/OMB) Unknown or Not Reported	2 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	2 Participants n=16 Participants

PRIMARY outcome

Timeframe: Up to day 113

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=12 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M n=6 Participants Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M n=7 Participants Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M n=6 Participants Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW n=14 Participants Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W n=7 Participants Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW n=4 Participants Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo n=15 Participants Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest AEs	75.0 Percentage of Participants	87.5 Percentage of Participants	37.5 Percentage of Participants	75.0 Percentage of Participants	87.5 Percentage of Participants	50.0 Percentage of Participants	58.3 Percentage of Participants	33.3 Percentage of Participants	85.7 Percentage of Participants	66.7 Percentage of Participants	71.4 Percentage of Participants	57.1 Percentage of Participants	75.0 Percentage of Participants	53.3 Percentage of Participants
Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest AEs of Special Interest	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants

PRIMARY outcome

Timeframe: Screening, Days -1, 2, 8, 15, 29, 85

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=12 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1 SGOT/AST - High	0 Percentage of Participants	0 Percentage of Participants	12.5 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1 Chloride - Low	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	8.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1 HDL Cholesterol - Low	0 Percentage of Participants	12.5 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1 Triglycerides - High	12.5 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Screening, Days -1, 2, 8, 15, 29, at discontinuation, Days 36, 43, 57, 85, 113

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=15 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2 SGOT/AST - High	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2 Glucose, Fasting - High	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2 SGPT/ALT - High	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2 Bicorbonate HCO3 - Low	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2 Activated Partial Thromboplastin Time - High	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2 Triglycerides - High	100 Percentage of Participants	—	—	—	0 Percentage of Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF \> 500 msec, or \> 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=12 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Baseline	12.5 Percentage of Participants	50.0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	37.5 Percentage of Participants	25.0 Percentage of Participants	16.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Day 1 - 1h	37.5 Percentage of Participants	50.0 Percentage of Participants	12.5 Percentage of Participants	25.0 Percentage of Participants	37.5 Percentage of Participants	25.0 Percentage of Participants	41.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Day 1 - 4h	25.0 Percentage of Participants	25.0 Percentage of Participants	12.5 Percentage of Participants	25.0 Percentage of Participants	25.0 Percentage of Participants	12.5 Percentage of Participants	50.0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Day 1 - 8h	37.5 Percentage of Participants	50.0 Percentage of Participants	25.0 Percentage of Participants	12.5 Percentage of Participants	25.0 Percentage of Participants	25.0 Percentage of Participants	58.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Day 1 - 12h	25.0 Percentage of Participants	50.0 Percentage of Participants	25.0 Percentage of Participants	25.0 Percentage of Participants	37.5 Percentage of Participants	12.5 Percentage of Participants	58.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Day 2 - 24h	37.5 Percentage of Participants	50.0 Percentage of Participants	12.5 Percentage of Participants	12.5 Percentage of Participants	25.0 Percentage of Participants	25.0 Percentage of Participants	50.0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Day 8 - 168h	12.5 Percentage of Participants	50.0 Percentage of Participants	25.0 Percentage of Participants	37.5 Percentage of Participants	25.0 Percentage of Participants	25.0 Percentage of Participants	41.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Follow-up Day 15	12.5 Percentage of Participants	12.5 Percentage of Participants	12.5 Percentage of Participants	25.0 Percentage of Participants	12.5 Percentage of Participants	12.5 Percentage of Participants	16.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Follow-up Day 29	25.0 Percentage of Participants	25.0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	25.0 Percentage of Participants	36.4 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 Extended Follow-Up	0 Percentage of Participants	12.5 Percentage of Participants	28.6 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	25.0 Percentage of Participants	50.0 Percentage of Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=15 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 2 - 24h	33.3 Percentage of Participants	28.6 Percentage of Participants	50.0 Percentage of Participants	57.1 Percentage of Participants	57.1 Percentage of Participants	50.0 Percentage of Participants	33.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 29 - 4h	50.0 Percentage of Participants	33.3 Percentage of Participants	16.7 Percentage of Participants	57.1 Percentage of Participants	66.7 Percentage of Participants	—	25.0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 30 - 24h	66.7 Percentage of Participants	16.7 Percentage of Participants	100 Percentage of Participants	50.0 Percentage of Participants	66.7 Percentage of Participants	—	41.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Baseline	33.3 Percentage of Participants	14.3 Percentage of Participants	50.0 Percentage of Participants	50.0 Percentage of Participants	100 Percentage of Participants	50.0 Percentage of Participants	46.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 1 - 1h	66.7 Percentage of Participants	42.9 Percentage of Participants	50.0 Percentage of Participants	57.1 Percentage of Participants	85.7 Percentage of Participants	75.0 Percentage of Participants	40.0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 1 - 4h	33.3 Percentage of Participants	42.9 Percentage of Participants	66.7 Percentage of Participants	64.3 Percentage of Participants	57.1 Percentage of Participants	50.0 Percentage of Participants	33.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 1 - 8h	50.0 Percentage of Participants	0 Percentage of Participants	33.3 Percentage of Participants	50.0 Percentage of Participants	100 Percentage of Participants	25.0 Percentage of Participants	26.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 8	66.7 Percentage of Participants	57.1 Percentage of Participants	50.0 Percentage of Participants	57.1 Percentage of Participants	66.7 Percentage of Participants	25.0 Percentage of Participants	33.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 15	—	—	—	50.0 Percentage of Participants	83.3 Percentage of Participants	50.0 Percentage of Participants	71.4 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 22	—	—	—	50.0 Percentage of Participants	—	75.0 Percentage of Participants	80.0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 22 - 1h	—	—	—	—	—	75.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 22 - 8h	—	—	—	—	—	50.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 23 - 24h	—	—	—	—	—	50.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 29	66.7 Percentage of Participants	50.0 Percentage of Participants	83.3 Percentage of Participants	50.0 Percentage of Participants	83.3 Percentage of Participants	—	50.0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 29 - 1h	83.3 Percentage of Participants	16.7 Percentage of Participants	50.0 Percentage of Participants	64.3 Percentage of Participants	83.3 Percentage of Participants	—	58.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Day 29 - 8h	16.7 Percentage of Participants	0 Percentage of Participants	66.7 Percentage of Participants	64.3 Percentage of Participants	66.7 Percentage of Participants	—	16.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Follow-up Day 36	—	—	—	—	—	75.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Follow-up Day 43	83.3 Percentage of Participants	14.3 Percentage of Participants	16.7 Percentage of Participants	57.1 Percentage of Participants	57.1 Percentage of Participants	—	38.5 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Follow-up Day 50	—	—	—	—	—	50.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Follow-up Day 57	66.7 Percentage of Participants	14.3 Percentage of Participants	66.7 Percentage of Participants	57.1 Percentage of Participants	71.4 Percentage of Participants	—	53.8 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Follow-up Day 78	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Follow-up Day 85	33.3 Percentage of Participants	14.3 Percentage of Participants	66.7 Percentage of Participants	50.0 Percentage of Participants	57.1 Percentage of Participants	—	38.5 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Follow-up Day 106	—	—	—	—	—	50.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 Follow-up Day 113	66.7 Percentage of Participants	14.3 Percentage of Participants	50.0 Percentage of Participants	42.9 Percentage of Participants	71.4 Percentage of Participants	—	46.2 Percentage of Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=12 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Baseline	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Day 1 - 1h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Day 1 - 4h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Day 1 - 8h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Day 1 - 12h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Day 2 - 24h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Day 8 - 168h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	12.5 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Follow-up Day 15	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Follow-up Day 29	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 Extended Follow-Up	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=12 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Day 2 - 24h	12.5 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Day 8 - 168h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	12.5 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Follow-up Day 15	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Follow-up Day 29	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Extended Follow-Up	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Baseline	12.5 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Day 1 - 1h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Day 1 - 4h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Day 1 - 8h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 Day 1 - 12h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=15 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 2 - 24h	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 8	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 15	—	—	—	7.1 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 22	—	—	—	7.1 Percentage of Participants	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 22 - 1h	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 22 - 8h	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 23 - 24h	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 29	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 29 - 1h	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	8.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 29 - 4h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	8.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Baseline	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 1 - 1h	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 1 - 4h	0 Percentage of Participants	0 Percentage of Participants	33.3 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 1 - 8h	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 29 - 8h	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Day 30 - 24h	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Follow-up Day 36	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Follow-up Day 43	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Follow-up Day 50	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Follow-up Day 57	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Follow-up Day 78	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Follow-up Day 85	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Follow-up Day 106	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 Follow-up Day 113	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=15 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 8	16.7 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	6.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Follow-up Day 78	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Follow-up Day 85	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	7.1 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Follow-up Day 106	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Follow-up Day 113	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	14.3 Percentage of Participants	—	15.4 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Baseline	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	6.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 1 - 1h	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	6.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 1 - 4h	16.7 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	6.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 1 - 8h	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	6.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 2 - 24h	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	6.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 15	—	—	—	7.1 Percentage of Participants	0 Percentage of Participants	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 22	—	—	—	7.1 Percentage of Participants	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 22 - 1h	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 22 - 8h	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 23 - 24h	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 29	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 29 - 1h	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 29 - 4h	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 29 - 8h	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Day 30 - 24h	0 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Follow-up Day 36	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Follow-up Day 43	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Follow-up Day 50	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 Follow-up Day 57	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	7.1 Percentage of Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113

Population: Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=15 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 30 - 24h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	8.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Baseline	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 1 - 1h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 1 - 4h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 1 - 8h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	14.3 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 2 - 24h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 8	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 15	—	—	—	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 22	—	—	—	7.1 Percentage of Participants	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 22 - 1h	—	—	—	—	—	25.0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 22 - 8h	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 23 - 24h	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 29	0 Percentage of Participants	0 Percentage of Participants	16.7 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	8.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 29 - 1h	0 Percentage of Participants	0 Percentage of Participants	33.3 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	8.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 29 - 4h	0 Percentage of Participants	0 Percentage of Participants	33.3 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	8.3 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Day 29 - 8h	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Follow-up Day 36	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Follow-up Day 43	0 Percentage of Participants	0 Percentage of Participants	0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Follow-up Day 50	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Follow-up Day 57	0 Percentage of Participants	0 Percentage of Participants	50.0 Percentage of Participants	7.1 Percentage of Participants	0 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Follow-up Day 78	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Follow-up Day 85	0 Percentage of Participants	14.3 Percentage of Participants	33.3 Percentage of Participants	7.1 Percentage of Participants	14.3 Percentage of Participants	—	7.7 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Follow-up Day 106	—	—	—	—	—	0 Percentage of Participants	0 Percentage of Participants	—	—	—	—	—	—	—
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 Follow-up Day 113	0 Percentage of Participants	0 Percentage of Participants	33.3 Percentage of Participants	0 Percentage of Participants	14.3 Percentage of Participants	—	0 Percentage of Participants	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-8

Population: The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.

Cmax values are the the peak plasma concentration reached after administration of RO7062931.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Maximum Plasma Concentration (Cmax) After Single Ascending Doses - Part 1	7.78 nmol/L Geometric Coefficient of Variation 40.2	19.53 nmol/L Geometric Coefficient of Variation 28.1	41.69 nmol/L Geometric Coefficient of Variation 30.8	103.68 nmol/L Geometric Coefficient of Variation 34.0	312.53 nmol/L Geometric Coefficient of Variation 22.2	153.53 nmol/L Geometric Coefficient of Variation 25.3	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-113

Cmax values are the the peak plasma concentration reached after administration of RO7062931.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Cmax After Multiple Ascending Doses - Part 2 First Dose	21.17 mg/kg Geometric Coefficient of Variation 46.4	72.44 mg/kg Geometric Coefficient of Variation 57.8	169.56 mg/kg Geometric Coefficient of Variation 43.9	158.61 mg/kg Geometric Coefficient of Variation 37.9	218.05 mg/kg Geometric Coefficient of Variation 64.4	232.54 mg/kg Geometric Coefficient of Variation 10.6	—	—	—	—	—	—	—	—
Cmax After Multiple Ascending Doses - Part 2 Last Dose	18.56 mg/kg Geometric Coefficient of Variation 69.1	82.11 mg/kg Geometric Coefficient of Variation 37.6	194.72 mg/kg Geometric Coefficient of Variation 15.8	164.83 mg/kg Geometric Coefficient of Variation 65.0	190.83 mg/kg Geometric Coefficient of Variation 35.6	250.72 mg/kg Geometric Coefficient of Variation 23.4	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-8

Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Time to Reach Maximum Plasma Concentration (Tmax) After Single-Ascending Doses - Part 1	1.75 Hours (h) Interval 1.0 to 3.0	2.00 Hours (h) Interval 1.5 to 2.0	3.00 Hours (h) Interval 1.5 to 6.0	2.00 Hours (h) Interval 2.0 to 6.0	3.00 Hours (h) Interval 2.0 to 6.0	2.00 Hours (h) Interval 2.0 to 6.0	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-113

Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Tmax After Multiple Ascending Doses - Part 2 First Dose	2.98 Hours (h) Interval 0.5 to 7.9	2.00 Hours (h) Interval 2.0 to 4.0	2.00 Hours (h) Interval 1.9 to 8.0	4.00 Hours (h) Interval 1.9 to 6.0	3.98 Hours (h) Interval 1.9 to 5.9	2.00 Hours (h) Interval 1.9 to 2.0	—	—	—	—	—	—	—	—
Tmax After Multiple Ascending Doses - Part 2 Last Dose	3.04 Hours (h) Interval 2.0 to 7.7	3.00 Hours (h) Interval 2.0 to 6.0	4.00 Hours (h) Interval 2.0 to 4.1	1.97 Hours (h) Interval 1.9 to 7.8	2.94 Hours (h) Interval 1.9 to 5.7	2.95 Hours (h) Interval 2.0 to 4.0	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-8

AUC0-inf was calculated based on non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) After Single-Ascending Doses - Part 1	39.21 h*nmol/L Geometric Coefficient of Variation 14.0	92.72 h*nmol/L Geometric Coefficient of Variation 14.1	308.48 h*nmol/L Geometric Coefficient of Variation 13.2	792.36 h*nmol/L Geometric Coefficient of Variation 19.1	2478.56 h*nmol/L Geometric Coefficient of Variation 8.7	1257.23 h*nmol/L Geometric Coefficient of Variation 19.4	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1,22,29

AUC0-inf was calculated based on non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
AUC0-inf After Multiple Ascending Doses - Part 2 Day 1	175.30 h*nmol/L Geometric Coefficient of Variation 6.9	567.07 h*nmol/L Geometric Coefficient of Variation 41.5	1606.49 h*nmol/L Geometric Coefficient of Variation 26.4	1434.39 h*nmol/L Geometric Coefficient of Variation 13.6	1857.98 h*nmol/L Geometric Coefficient of Variation 41.2	2371.66 h*nmol/L Geometric Coefficient of Variation 15.2	—	—	—	—	—	—	—	—
AUC0-inf After Multiple Ascending Doses - Part 2 Day 22	—	—	—	—	—	2199.57 h*nmol/L Geometric Coefficient of Variation 16.7	—	—	—	—	—	—	—	—
AUC0-inf After Multiple Ascending Doses - Part 2 Day 29	180.34 h*nmol/L Geometric Coefficient of Variation 13.3	680.80 h*nmol/L Geometric Coefficient of Variation 8.8	1636.76 h*nmol/L Geometric Coefficient of Variation 11.0	1475.19 h*nmol/L Geometric Coefficient of Variation 30.3	1541.85 h*nmol/L Geometric Coefficient of Variation 26.9	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-8

AUC0-last was calculated based on non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=7 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) After Single Ascending Doses - Part 1	39.10 (hr*nmol/L) Geometric Coefficient of Variation 14.0	92.62 (hr*nmol/L) Geometric Coefficient of Variation 14.1	310.69 (hr*nmol/L) Geometric Coefficient of Variation 12.9	789.27 (hr*nmol/L) Geometric Coefficient of Variation 19.1	2448.99 (hr*nmol/L) Geometric Coefficient of Variation 8.1	1253.26 (hr*nmol/L) Geometric Coefficient of Variation 19.3	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1,22,29

AUC0-last was calculated based on non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
AUC0-last After Multiple Ascending Doses - Part 2 Day 1	147.30 hr*nmol/L Geometric Coefficient of Variation 28.8	555.16 hr*nmol/L Geometric Coefficient of Variation 34.8	1603.81 hr*nmol/L Geometric Coefficient of Variation 26.4	1458.57 hr*nmol/L Geometric Coefficient of Variation 12.9	1929.56 hr*nmol/L Geometric Coefficient of Variation 49.9	2279.78 hr*nmol/L Geometric Coefficient of Variation 14.7	—	—	—	—	—	—	—	—
AUC0-last After Multiple Ascending Doses - Part 2 Day 22	—	—	—	—	—	2195.18 hr*nmol/L Geometric Coefficient of Variation 16.6	—	—	—	—	—	—	—	—
AUC0-last After Multiple Ascending Doses - Part 2 Day 29	141.35 hr*nmol/L Geometric Coefficient of Variation 52.6	662.95 hr*nmol/L Geometric Coefficient of Variation 20.5	1633.64 hr*nmol/L Geometric Coefficient of Variation 11.0	1470.64 hr*nmol/L Geometric Coefficient of Variation 30.5	1539.73 hr*nmol/L Geometric Coefficient of Variation 27.0	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-8

T1/2 was calculated based on non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Terminal Elimination Half-Life (t1/2) After Single Ascending Doses - Part 1	3.77 Hours (h) Geometric Coefficient of Variation 65.4	3.99 Hours (h) Geometric Coefficient of Variation 38.3	44.32 Hours (h) Geometric Coefficient of Variation 170.4	97.06 Hours (h) Geometric Coefficient of Variation 35.9	115.24 Hours (h) Geometric Coefficient of Variation 60.4	85.70 Hours (h) Geometric Coefficient of Variation 29.7	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-113

T1/2 was calculated based on non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Terminal Elimination Half-Life (t1/2) After Multiple Ascending Doses - Part 2 First Dose	2.99 Hours (h) Geometric Coefficient of Variation 13.1	18.81 Hours (h) Geometric Coefficient of Variation 32.0	88.59 Hours (h) Geometric Coefficient of Variation 94.1	NA Hours (h) Geometric Coefficient of Variation NA Insufficient data to estimate parameter.	37.96 Hours (h) Geometric Coefficient of Variation 62.1	15.09 Hours (h) Geometric Coefficient of Variation 4.3	—	—	—	—	—	—	—	—
Terminal Elimination Half-Life (t1/2) After Multiple Ascending Doses - Part 2 Last Dose	3.86 Hours (h) Geometric Coefficient of Variation 107.8	NA Hours (h) Geometric Coefficient of Variation NA Insufficient data to estimate parameter.	119.45 Hours (h) Geometric Coefficient of Variation 58.8	172.20 Hours (h) Geometric Coefficient of Variation 26.7	62.08 Hours (h) Geometric Coefficient of Variation 91.8	152.79 Hours (h) Geometric Coefficient of Variation 28.7	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-8

Apparent oral clearance was calculated from Dose/AUCinf.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Total Clearance (CL) After Single Ascending Doses - Part 1	26.68 L/h Geometric Coefficient of Variation 21.3	35.97 L/h Geometric Coefficient of Variation 24.7	37.36 L/h Geometric Coefficient of Variation 29.9	26.9 L/h Geometric Coefficient of Variation 20.8	16.15 L/h Geometric Coefficient of Variation 18.4	23.46 L/h Geometric Coefficient of Variation 19.3	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-113

Apparent oral clearance was calculated from Dose/AUCinf.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Total Clearance (CL) After Multiple Ascending Doses - Part 2	31.12 L/h Geometric Coefficient of Variation 10.2	NA L/h Geometric Coefficient of Variation NA Insufficient data to estimate parameter.	18.12 L/h Geometric Coefficient of Variation 27.2	21.76 L/h Geometric Coefficient of Variation 42.0	19.37 L/h Geometric Coefficient of Variation 43.5	18.75 L/h Geometric Coefficient of Variation 34.5	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-8

Vss was calculated from dose/AUCinf

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=8 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Volume of Distribution (Vss) After Single Ascending Doses - Part 1	145.22 Liters (L) Geometric Coefficient of Variation 61.2	206.96 Liters (L) Geometric Coefficient of Variation 35.2	2389.08 Liters (L) Geometric Coefficient of Variation 228.8	3767.16 Liters (L) Geometric Coefficient of Variation 34.4	2684.87 Liters (L) Geometric Coefficient of Variation 56.8	2900.19 Liters (L) Geometric Coefficient of Variation 13.9	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-113

Vss was calculated from dose/AUCinf

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Volume of Distribution (Vss) After Multiple Ascending Doses - Part 2	173.27 Liters (L) Geometric Coefficient of Variation 119.8	NA Liters (L) Geometric Coefficient of Variation NA Insufficient data to estimate parameter.	3122.3 Liters (L) Geometric Coefficient of Variation 46.8	5405.97 Liters (L) Geometric Coefficient of Variation 53.8	1734.46 Liters (L) Geometric Coefficient of Variation 86.9	4131.91 Liters (L) Geometric Coefficient of Variation 22.9	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Hours 0-4, 0-8, 0-12, and 0-24

Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=8 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=8 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=8 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=8 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=8 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1 Accumulation Interval 0-12 (h)	10399.04 pmol Geometric Coefficient of Variation 40.7	28335.16 pmol Geometric Coefficient of Variation 27.6	143182.68 pmol Geometric Coefficient of Variation 42.8	249381.19 pmol Geometric Coefficient of Variation 72.6	1148178.69 pmol Geometric Coefficient of Variation 38.2	592833.26 pmol Geometric Coefficient of Variation 13.5	—	—	—	—	—	—	—	—
Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1 Accumulation Interval 0-4 (h)	6180.14 pmol Geometric Coefficient of Variation 85.0	17111.86 pmol Geometric Coefficient of Variation 29.4	50248.03 pmol Geometric Coefficient of Variation 97.0	108870.36 pmol Geometric Coefficient of Variation 95.4	317169.45 pmol Geometric Coefficient of Variation 62.1	206781.39 pmol Geometric Coefficient of Variation 34.4	—	—	—	—	—	—	—	—
Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1 Accumulation Interval 0-8 (h)	9028.41 pmol Geometric Coefficient of Variation 50.4	25608.73 pmol Geometric Coefficient of Variation 25.2	117472.78 pmol Geometric Coefficient of Variation 52.5	202181.27 pmol Geometric Coefficient of Variation 80.6	930967.60 pmol Geometric Coefficient of Variation 42.2	458520.65 pmol Geometric Coefficient of Variation 21.2	—	—	—	—	—	—	—	—
Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1 Accumulation Interval 0-24 (h)	11043.57 pmol Geometric Coefficient of Variation 38.9	29221.86 pmol Geometric Coefficient of Variation 28.6	155256.07 pmol Geometric Coefficient of Variation 38.9	275688.93 pmol Geometric Coefficient of Variation 68.3	1235241.74 pmol Geometric Coefficient of Variation 33.9	647368.11 pmol Geometric Coefficient of Variation 12.1	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-113

Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=7 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=14 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Cumulative Amount Excreted Unchanged in Urine (Ae) After Multiple Ascending Doses - Part 2	48.45 nmol Geometric Coefficient of Variation 22.48	183.38 nmol Geometric Coefficient of Variation 67.53	587.05 nmol Geometric Coefficient of Variation 294.65	790.51 nmol Geometric Coefficient of Variation 402.06	615.33 nmol Geometric Coefficient of Variation 432.78	1146.02 nmol Geometric Coefficient of Variation 177.61	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Days 1-113

Population: Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.

HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=7 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=7 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=15 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Change From Baseline of Quantitative HBsAg (qHBsAg) (log10) After Multiple Ascending Doses - Part 2 Baseline value	3.39 IU/mL Standard Deviation 0.360	3.37 IU/mL Standard Deviation 0.272	3.37 IU/mL Standard Deviation 0.134	3.68 IU/mL Standard Deviation 0.381	3.76 IU/mL Standard Deviation 0.285	3.69 IU/mL Standard Deviation 0.274	3.55 IU/mL Standard Deviation 0.421	—	—	—	—	—	—	—
Change From Baseline of Quantitative HBsAg (qHBsAg) (log10) After Multiple Ascending Doses - Part 2 Final change from baseline	-0.04 IU/mL Standard Deviation 0.057	-0.05 IU/mL Standard Deviation 0.072	-0.03 IU/mL Standard Deviation 0.053	-0.09 IU/mL Standard Deviation 0.090	-0.02 IU/mL Standard Deviation 0.070	-0.16 IU/mL Standard Deviation 0.088	-0.01 IU/mL Standard Deviation 0.046	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 - Day 113

Population: Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.

HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.

Outcome measures

Outcome measures
Measure	Part 1 - RO7062931 0.1 mg/kg n=6 Participants Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.	Part 1 - RO7062931 0.3 mg/kg n=6 Participants Participants received a single SC injection of 0.3 mg/kg RO7062931.	Part 1 - RO7062931 1.0 mg/kg n=6 Participants Participants received a single SC injection of 1.0 mg/kg RO7062931.	Part 1 - RO7062931 2.0 mg/kg n=14 Participants Participants received a single SC injection of 2.0 mg/kg RO7062931.	Part 1 - RO7062931 3.0 mg/kg n=6 Participants Participants received a single SC injection of 3.0 mg/kg RO7062931.	Part 1 - RO7062931 4.0 mg/kg n=4 Participants Participants received a single SC injection of 4.0 mg/kg RO7062931.	Part 1 - Placebo n=13 Participants Participants received a single SC injection of placebo matched to RO7062931.	Part 2a - RO7062931 0.5 mg/kg Q1M Participants received two QM SC injections of 0.5 mg/kg RO7062931.	Part 2a - RO7062931 1.5 mg/kg Q1M Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.	Part 2a - RO7062931 3.0 mg/kg Q1M Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg QW Participants received five QW SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 3.0 mg/kg Q2W Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.	Part 2b - RO7062931 4.0 mg/kg QW Participants received four QW SC injections of 4.0 mg/kg RO7062931.	Part 2 - Placebo Participants received SC placebo matched to RO7062931 over a 4-week period.
Summary of Maximum qHBsAg Decrease on Days 1-113 - Part 2	-0.105 IU/mL Standard Deviation 0.0325	-0.360 IU/mL Standard Deviation 0.3752	-0.279 IU/mL Standard Deviation 0.0988	-0.495 IU/mL Standard Deviation 0.2093	-0.394 IU/mL Standard Deviation 0.1586	-0.336 IU/mL Standard Deviation 0.1685	-0.101 IU/mL Standard Deviation 0.0714	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 - Day 113

Population: Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.

HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.